We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.71%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$33.3B
AUM Growth
-$783M
(-2.3%)
Cap. Flow
-$715M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
15.9%
Holding
3,039
New
28
Increased
1,056
Reduced
1,268
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$29M |
| 2 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$14M |
| 3 |
Microsoft
MSFT
|
+$10.8M |
| 4 |
Meta Platforms (Facebook)
META
|
+$10.5M |
| 5 |
iShares Russell 1000 Growth ETF
IWF
|
+$6.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$34.4M |
| 2 |
FRX
FOREST LABORATORIES INC
FRX
|
+$32.2M |
| 3 |
ExxonMobil
XOM
|
+$23.9M |
| 4 |
Warner Bros
WBD
|
+$15.4M |
| 5 |
RTX Corp
RTX
|
+$13.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.81% |
| 2 | Financials | 14.8% |
| 3 | Healthcare | 13.73% |
| 4 | Industrials | 10.72% |
| 5 | Energy | 8.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVU
976
DELISTED
SUPERVALU Inc.
SVU
| $3.4M | 0.01% |
54,300
+775
| +1% | +$49.8K |
|
977
Pacira BioSciences
PCRX
$1.04B
| $3.39M | 0.01% |
35,008
+140
| +0.4% | +$13.6K |
|
|
CRR
978
DELISTED
Carbo Ceramics Inc.
CRR
| $3.39M | 0.01% |
57,281
-6,124
| -10% | -$699K |
|
979
Vail Resorts
MTN
$5.32B
| $3.38M | 0.01% |
38,919
+480
| +1% | +$38.1K |
|
980
Abercrombie & Fitch
ANF
$4.42B
| $3.37M | 0.01% |
92,842
-1,015
| -1% | -$41.3K |
|
981
Associated Banc-Corp
ASB
$5.83B
| $3.37M | 0.01% |
193,505
+410
| +0.2% | +$7.42K |
|
|
CAB
982
DELISTED
Cabela's Inc
CAB
| $3.35M | 0.01% |
56,893
+50
| +0.1% | +$2.99K |
|
|
HSNI
983
DELISTED
HSN, Inc.
HSNI
| $3.35M | 0.01% |
54,584
+470
| +0.9% | +$27.6K |
|
|
QGENF
984
DELISTED
QIAGEN NV
QGENF
| $3.35M | 0.01% |
147,126
+70
| +0% | +$1.59K |
|
985
Advanced Micro Devices
AMD
$776B
| $3.34M | 0.01% |
980,275
-1,303
| -0.1% | -$5.27K |
|
|
MPT
986
Medical Properties Trust
MPT
$2.77B
| $3.34M | 0.01% |
272,669
-80
| -0% | -$1.06K |
|
987
MillerKnoll
MLKN
$1.53B
| $3.32M | 0.01% |
111,308
+5,785
| +5% | +$174K |
|
|
BRCD
988
DELISTED
Brocade Communications Systems, Inc. NEW
BRCD
| $3.31M | 0.01% |
304,271
+2,700
| +0.9% | +$26.3K |
|
|
SGEN
989
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.31M | 0.01% |
88,889
-123
| -0.1% | -$4.84K |
|
990
Nu Skin
NUS
$252M
| $3.3M | 0.01% |
73,369
+22,417
| +44% | +$1.19M |
|
991
Worthington Enterprises
WOR
$2.75B
| $3.3M | 0.01% |
143,988
+1,735
| +1% | +$43.1K |
|
|
CPHD
992
DELISTED
Cepheid Inc
CPHD
| $3.3M | 0.01% |
74,984
+865
| +1% | +$36.5K |
|
993
Sally Beauty Holdings
SBH
$1.43B
| $3.3M | 0.01% |
120,592
+687
| +0.6% | +$18.2K |
|
|
CEB
994
DELISTED
CEB Inc.
CEB
| $3.3M | 0.01% |
54,953
+70
| +0.1% | +$4.58K |
|
995
Hexcel
HXL
$7.79B
| $3.3M | 0.01% |
83,114
+257
| +0.3% | +$10.1K |
|
996
Manhattan Associates
MANH
$11.2B
| $3.3M | 0.01% |
98,757
+530
| +0.5% | +$16.6K |
|
997
Take-Two Interactive
TTWO
$45.4B
| $3.3M | 0.01% |
143,020
-1,230
| -0.9% | -$27.9K |
|
998
Toro Company
TTC
$8.75B
| $3.29M | 0.01% |
111,132
+534
| +0.5% | +$16.3K |
|
999
AXIS Capital
AXS
$7.68B
| $3.29M | 0.01% |
69,466
+690
| +1% | +$31.9K |
|
1000
Voya Financial
VOYA
$9.01B
| $3.29M | 0.01% |
84,087
+2,275
| +3% | +$86.3K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2014 Portfolio in Review
As of Q3 2014, RhumbLine Advisers held 3,039 positions worth $33.3B, down 2.3% from $34.1B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Trading was light in Q3 2014: portfolio turnover was 2.8%. RhumbLine Advisers opened 28 new positions and exited 57, leaving the 3,039-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2014 buy was Discovery, Inc. Series C Common Stock: 346,925 shares worth $12.9M.
- RhumbLine Advisers added most to Allergan plc in Q3 2014, an estimated $29M increase.
- RhumbLine Advisers's biggest Q3 2014 reduction was Apple, cutting an estimated $34.4M.
- RhumbLine Advisers fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $32.2M.
- RhumbLine Advisers's ten largest holdings make up 16% of its $33.3B portfolio in Q3 2014.
- RhumbLine Advisers opened 28 new positions and closed 57 in Q3 2014.
- RhumbLine Advisers's portfolio value fell 2.3% quarter-over-quarter to $33.3B.
Based on RhumbLine Advisers's 13F filing for Q3 2014, filed 12 Nov 2014.